Breaking News

Frontage Expands Development Services

April 3, 2013

Gains broader DEA license for pain therapeutics and controlled-substances

Frontage Laboratories has received approval to expand its U.S. Drug Enforcement Agency (DEA) license to include formulation development and manufacture of GMP clinical trial materials (CTM) for pain therapeutics and controlled-substances. For the expanded DEA license, Frontage upgraded its facilities, security, and personnel procedures at both of its Exton, PA sites.
Frontage supports companies developing DEA Schedules I–V controlled substances and provides analytical development and GMP analytical testing, clinical trial services and bioanalytical support of clinical and preclinical samples.

blog comments powered by Disqus